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Thyroid Hormone Therapy for Older Adults with Subclinical 
Hypothyroidism
To the Editor: We would note some limitations 
in the otherwise informative report by Stott et al. 
on the Thyroid Hormone Replacement for Un-
treated Older Adults with Subclinical Hypothy-
roidism — A Randomized Placebo Controlled 
Trial (TRUST) (June 29 issue).1 The results for 
free thyroxine were reported only as pretreatment 
levels at baseline; values after treatment would 
have been helpful in interpreting the data. Also, 
lipid levels should have been included in the car-
diovascular risk assessment, since hypothyroidism 
is a known cause of potentially reversible hyper-
lipidemia.2 Patients with hyperlipidemia and sub-
clinical hypothyroidism could well be candidates 
for a trial of thyroxine supplementation.
Furthermore, the association between subclini-
cal hypothyroidism and heart disease remains 
unclear.3,4 Stott et al. observed an imbalance 
between the levothyroxine group and the placebo 
group in the point estimates for cardiovascular 
deaths and deaths from any cause. This trend, 
although not statistically significant owing to the 
small numbers of patients, is nonetheless worri-
some. Were the deaths from any cause adjudi-
cated? If so, how many were sudden deaths, and 
how were those patients represented in the levo-
thyroxine group and the placebo group? Such 
additional data could be valuable when clinicians 
are evaluating the potential risks associated with 
the discretionary supplementation of thyroid hor-
mone in elderly patients with subclinical hypo-
thyroidism.
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To the Editor: On the basis of previous obser-
vational findings,1 the TRUST trial was initiated to 
provide evidence as to whether subclinical hypo-
thyroidism is causally linked to disease in old 
age. Despite being the largest trial to date with 
737 participants, it was underpowered to address 
the association between hypothyroidism and car-
diovascular disease, as highlighted in the Discus-
sion section.
We conducted a two-sample mendelian ran-
domization study with 20 genetic variants for 
circulating levels of thyrotropin and 3 genetic 
variants for circulating levels of free thyroxine2 
on summary data of a genomewide association 
study consisting of 60,801 case patients with 
coronary artery disease and 123,504 controls 
from the CARDIoGRAMplusC4D Consortium.3 
On the basis of statistical analyses that have been 
described previously,4 we found no evidence for a 
causal relationship between circulating levels of 
thyrotropin or free thyroxine and the risk of coro-
nary artery disease (odds ratio of 0.99 per stan-
dard deviation of increase in thyrotropin, P = 0.83; 
and odds ratio of 1.02 per standard deviation of 
increase in free thyroxine, P = 0.74). Thus, even 
if the TRUST trial had been considerably larger 
and had longer follow-up, it is likely that the 
investigators would have found no beneficial ef-
fect of levothyroxine treatment on the incidence 
of coronary artery disease, similar to their find-
ings with respect to other outcomes.
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To the Editor: Subclinical hypothyroidism is a 
common biochemical diagnosis, defined as in-
creased levels of serum thyrotropin with normal 
levels of serum free thyroxine. The use of the 
commonly employed direct immunoassay to mea-
sure thyrotropin and free thyroxine has some 
major limitations.1 Such limitations are particu-
larly due to changes in binding protein concentra-
tions that occur in many physiologic and disease 
states and a weak inverse linear log relationship 
to thyrotropin in thyroid disorders, factors that 
frequently do not fit in with the clinical presenta-
tion.2 The measurements of free thyroxine and 
free triiodothyronine followed by liquid chroma-
tography–mass spectrometry are the most clin-
ically relevant for the evaluation of thyroid dis-
orders and can be achieved with the use of 
equilibrium dialysis or ultrafiltration to measure 
the free thyroid concentrations.3 In one study, ap-
proximately two thirds of the patients with sub-
clinical hypothyroidism (as ascertained by means 
of immunoassays) were found to have true hypo-
thyroidism when these definitive mass spectro-
metric methods were used.4 Liquid chromatogra-
phy–mass spectrometry assays are highly specific, 
sensitive, and precise and can detect hormones 
found in low concentrations, with a higher and 
more accurate correlation coefficient between 
free thyroxine and the log-transformed thyrotro-
pin level than that obtained on immunoassays.5 
The use of such assays can avoid the misclassifi-
cation of thyroid disorders, which could have an 
effect on the care of patients and on research.
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To the Editor: Stott et al. conclude that levothy-
roxine provided no apparent benefits in older 
persons with subclinical hypothyroidism. How-
ever, even high-normal levels of thyrotropin 
(>2.5 mIU per liter) are associated with meta-
bolic risk factors.1 Moreover, geriatric patients 
are typically taking multiple drugs. The intake 
of levothyroxine too close to the consumption of 
food or drink can cause relevant fluctuations in 
the results on thyroid-function testing.2,3 Such 
fluctuations can result in on-and-off overreplace-
ment, with clinical symptoms of thyrotoxicosis 
that may have obscured the beneficial effects of 
levothyroxine replacement. The trial protocol men-
tions that levothyroxine was prescribed to be 
taken “before breakfast” without further specifi-
cation of the precise timing of administration. 
We have implemented an update in the recent 
versions of the British National Formula suggest-
ing that levothyroxine should be taken at least 
30 minutes before breakfast and the intake of 
caffeine-containing beverages to facilitate more 
reliable absorption, a recommendation that is in 
line with those of other countries, including the 
United States.4 Outcomes of the trial by Stott et al. 
might have been different if the investigators had 
made more specific recommendations regarding 
the precise timing of levothyroxine intake, with 
possibly important implications for the treatment 
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of geriatric patients with subclinical hypothy-
roidism.
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The authors reply: Ogunsakin et al. ask for 
post-treatment free thyroxine values. Although we 
did not measure such levels routinely, we did re-
port levels in a subsample of the participants, in 
whom levels of free thyroxine were 2.3 pmol per 
liter higher in the levothyroxine group than in 
the placebo group (Table S2 in the Supplemen-
tary Appendix of our article, available with the 
full text at NEJM.org). We agree that lipid levels 
in our trial will be of great interest. The results 
of such assays will be included as part of our 
portfolio of work on the trial biobank.
Ogunsakin et al. note an imbalance between 
the levothyroxine group and the placebo group 
in the point estimates for cardiovascular deaths 
and deaths from any cause. There was 1 cardio-
vascular death plus 4 noncardiovascular deaths 
in the placebo group (during 577.9 person-years 
of follow-up) as compared with 2 and 8, respec-
tively, in the levothyroxine group (during 586.9 
person-years of follow-up). The confidence inter-
vals for the treatment effect are very wide (hazard 
ratio for death from any cause, 1.91; 95% confi-
dence interval, 0.65 to 5.60), so it is currently not 
possible to state whether levothyroxine treatment 
might be harmful to or indeed beneficial for 
these outcomes.
We agree with van Vliet et al. that our trial 
was underpowered to determine whether treat-
ment of subclinical hypothyroidism with levo-
thyroxine reduces the risk of cardiovascular 
disease. Mendelian randomization studies can 
provide useful information to help determine 
whether epidemiologic associations are poten-
tially causal, and we note the finding of their 
research with interest.
All the measures of thyrotropin and free thy-
roxine in our trial were determined by means of 
immunoassay with the use of established meth-
ods. Although analyses of thyrotropin on immu-
noassay platforms are considered to be reliable, 
the validity of immunoassay measures of free 
thyroxine has been questioned.1 The hypothesis 
of Hannah-Shmouni and Soldin — that the use 
of equilibrium dialysis or ultrafiltration assays 
to identify patients with low free thyroxine levels 
might help in identifying those who would bene-
fit from levothyroxine treatment — is interest-
ing but remains to be proven. We hope to ad-
dress this issue as part of our work on the trial 
biobank.
We agree with the comments of Weickert and 
Kyrou on the timing of levothyroxine adminis-
tration and absorption.2 Our simple instructions 
were to take the medicine before breakfast. 
However, since we adjusted the dose to achieve 
thyrotropin levels within the reference range, 
the timing of the receipt of levothyroxine should 
not have influenced the outcomes.
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